Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Natural killer (NK) cells attack many tumour cell lines, and are thought to have a critical role in anti-tumour immunity; however, the interaction between NK cells and tumour targets is poorly understood. The stimulatory lectin-like NKG2D receptor is expressed by NK cells, activated CD8+ T cells and by activated macrophages in mice. Several distinct cell-surface ligands that are related to class I major histocompatibility complex molecules have been identified, some of which are expressed at high levels by tumour cells but not by normal cells in adults. However, no direct evidence links the expression of these 'induced self' ligands with tumour cell rejection. Here we demonstrate that ectopic expression of the murine NKG2D ligands Rae1beta or H60 in several tumour cell lines results in potent rejection of the tumour cells by syngeneic mice. Rejection is mediated by NK cells and/or CD8+ T cells. The ligand-expressing tumour cells induce potent priming of cytotoxic T cells and sensitization of NK cells in vivo. Mice that are exposed to live or irradiated tumour cells expressing Rae1 or H60 are specifically immune to subsequent challenge with tumour cells that lack NKG2D ligands, suggesting application of the ligands in the design of tumour vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“NKG2D has been implicated in immune surveillance of tumors using transgenic models of spontaneous cancer as well as subcutaneous tumor transfer models (Cerwenka et al., 2001; Diefenbach et al., 2001; Guerra et al., 2008).”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Diefenbach et al., 2001
In the citing paper
“Previous studies from our laboratory demonstrated that transplanted tumor cells expressing NKG2D ligands are rejected by NK cells and, in some cases, T cells (Diefenbach et al., 2000, 2001, 2003)”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Diefenbach et al., 2001
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
Biology of Natural Killer Cells
Trinchieri, G. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60664-1 · Cited by 2,902
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818 · cited 1×
“However, this was not the case with irradiated ligand-negative B16-BL6 tumour cell”
BackgroundInnate Immunity: The Virtues of a Nonclonal System of Recognition
Medzhitov, R., & Janeway, C. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80412-2 · Cited by 2,434
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Counting Antigen-Specific CD8 T Cells: A Reevaluation of Bystander Activation during Viral Infection
Murali-Krishna, K., Altman, J. D., Suresh, M., Sourdive, D. J. D., Zajac, A. J., Miller, J. D., Slansky, J., & Ahmed, R. (1998) · Immunity · doi:10.1016/s1074-7613(00)80470-7 · Cited by 1,943 · cited 1×
“IFN-γ production was assayed by stimulating CTLs or NK cells with an equal number of target cells for 5–7 h and staining intracellular IFN-γ as describe”
MethodActivating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis
Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., Biassoni, R., & Moretta, L. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.197 · Cited by 1,778 · cited 1×
“It is unknown whether engagement of NKG2D in NK cells results in direct stimulation or supplies a co-stimulatory signal that acts in conjunction with signals from other stimulatory receptor”
BackgroundDemonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Cosman, D., Müllberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. J. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,232 · cited 1×
“Several distinct cell-surface ligands that are related to class I major histocompatibility complex molecules have been identifie”
BackgroundRole of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Cited by
Items 201–300 of 1,000
Natural Killer Cells and Solid Tumors
Stojanovic, A., & Cerwenka, A. (2011) · Journal of Innate Immunity · doi:10.1159/000325465 · Cited by 146
“Furthermore, higher numbers of NK cells were detected within NK cell-susceptible RMA-Rae-1 tumors as compared to NK cell-resistant RMA tumors [”
ResultGillard, G. O., Bivas-Benita, M., Hovav, A.-H., Grandpre, L. E., Panas, M. W., Seaman, M. S., Haynes, B. F., & Letvin, N. L. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002141 · Cited by 130
“The phenomenon of NK cell recognition and response to induced-self molecules has previously been implicated in both infections and oncogenesis[34,35,36,37], where ligands MULT1[38], H60[39], and Rae1[39,40]) for the activating receptor NKG2D are preferentially induced upon infection or cellular transformation[36,37,41…”
BackgroundMartinet, L., Jean, C., Dietrich, G., Fournié, J., & Poupot, R. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.05.002 · Cited by 147
The DNA damage response, immunity and cancer
Gasser, S., & Raulet, D. H. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.004 · Cited by 136
“In mice, ectopic expression of NKG2D ligands in rare cell lines that lack endogenous NKG2D ligands renders the cells sensitive to NK cell mediated attack in vitro and in vivo [9–11].”
BackgroundSelf-citationSoluble NKG2D ligands: prevalence, release, and functional impact
Salih, H. R., Holdenrieder, S., & Steinle, A. (2008) · Frontiers in bioscience · doi:10.2741/2939 · Cited by 145
ULBP6/RAET1L is an additional human NKG2D ligand
Eagle, R. A., Traherne, J. A., Hair, J. R., Jafferji, I., & Trowsdale, J. (2009) · European Journal of Immunology · doi:10.1002/eji.200939502 · Cited by 148
Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression
Song, H., Kim, J.-K., Cosman, D. J., & Choi, I. (2006) · Cellular Immunology · doi:10.1016/j.cellimm.2006.03.002 · Cited by 145
IL-21 Enhances Tumor Rejection through a NKG2D-Dependent Mechanism
Takaki, R., Hayakawa, Y., Nelson, A., Sivakumar, P. V., Hughes, S., Smyth, M. J., & Lanier, L. L. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2167 · Cited by 126
“Ectopic expression of RAE-1 on RMA T cell lymphoma cells renders the NK cell-insensitive tumor cells susceptible to NKG2Dmediated killing (13, 14).”
BackgroundNKG2D in NK and T Cell-Mediated Immunity
Ogasawara, K., & Lanier, L. L. (2005) · Journal of Clinical Immunology · doi:10.1007/s10875-005-8786-4 · Cited by 138
“In some cases, expression of NKG2D ligands on tumors can augment the generation of tumor-specific T cells (45, 49).”
Sangiolo, D., Martinuzzi, E., Todorovic, M., Vitaggio, K., Vallario, A., Jordaney, N., Carnevale‐Schianca, F., Capaldi, A., Geuna, M., Casorzo, L., et al. (2008) · International Immunology · doi:10.1093/intimm/dxn042 · Cited by 128
A basolateral sorting motif in the MICA cytoplasmic tail
Suemizu, H., Radosavljevic, M., Kimura, M., Sadahiro, S., Yoshimura, S., Bahram, S., & Inoko, H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052701099 · Cited by 136
Bozza, S., Bistoni, F., Gaziano, R., Pitzurra, L., Zelante, T., Bonifazi, P., Perruccio, K., Bellocchio, S., Neri, M., Iorio, A. M., et al. (2006) · Blood · doi:10.1182/blood-2006-03-009266 · Cited by 128
“However, optimal activation of NK cells in MCMV infection also requires the engagement of cell surface receptors,(48) such as the activating receptor NKG2D whose ligation can override the inhibitory signals provided by MHC class I engagement.(58) In MCMV-susceptible BALB/c mice, early NK cell responses are ineffective…”
BackgroundNrf2 Induces IL-17D to Mediate Tumor and Virus Surveillance
Saddawi-Konefka, R., Seelige, R., Gross, E. T. E., Levy, E., Searles, S. C., Washington, A., Santosa, E. K., Liu, B., O’Sullivan, T. E., Harismendy, O., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.075 · Cited by 126
“Moreover, NKG2D ligands are induced by viral infection (Shafi et al., 2011; Vivier et al., 2011) as well as being constitutively expressed on cancer cells (Diefenbach et al., 2001; Guerra et al., 2008).”
Markiewicz, M. A., Carayannopoulos, L. N., Naidenko, O. V., Matsui, K., Burack, R., Wise, E. L., Fremont, D. H., Allen, P. M., Yokoyama, W. M., Colonna, M., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.5.2825 · Cited by 126
“The NKG2D-mediated enhancement that we observed is consistent with other reports suggesting that this molecule can costimulate both mouse and human CD8 T cell responses (3, 5, 9, 16, 17, 47).”
BackgroundResultInfluentialGenetics, genomics, and evolutionary biology of NKG 2D ligands
Carapito, R., & Bahram, S. (2015) · Immunological Reviews · doi:10.1111/imr.12328 · Cited by 130
“In mice, it has indeed been shown that NK and/or CD8 T cells efficiently eliminate cancer cells expressing NKG2DLs (165, 166).”
BackgroundHuman Effector CD8+ T Lymphocytes Express TLR3 as a Functional Coreceptor
Tabiasco, J., Devêvre, E., Rufer, N., Salaun, B., Cerottini, J., Speiser, D. E., & Romero, P. J. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.12.8708 · Cited by 135
“However, in contrast with NKG2D, TLR3 directly recognizes viral components, whereas NK-activating receptor ligands are expressed by target cells upon viral infection, cellular stress, or transformation (35, 38).”
BackgroundSuppression of tumor formation in lymph nodes by L-selectin–mediated natural killer cell recruitment
Chen, S., Kawashima, H., Lowe, J. B., Lanier, L. L., & Fukuda, M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051473 · Cited by 114
“Indeed, NK cells were recruited to the peritoneal cavity by MHC class I–deficient tumor cells and tumors expressing NKG2D ligands, and then became activated at this site (36, 47, 48).”
BackgroundTissue-Resident NK Cells: Development, Maturation, and Clinical Relevance
Hashemi, E., & Malarkannan, S. (2020) · Cancers · doi:10.3390/cancers12061553 · Cited by 138
Gleimer, M., & Parham, P. (2003) · Immunity · doi:10.1016/s1074-7613(03)00272-3 · Cited by 141
Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis
Liu, G., Lu, S., Wang, X., Page, S. T., Higano, C. S., Plymate, S. R., Greenberg, N. M., Sun, S., Li, Z., & Wu, J. D. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69369 · Cited by 127
“Enforced expression of NKG2D ligand causes tumor cells to be rejected in syngeneic mice in a manner that is dependent on NK cells and, in some cases, primed CD8 T cells (6, 7).”
Dynamic response of cancer under the influence of immunological activity and therapy
de Vladar, H. P., & González, J. A. (2004) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2003.11.012 · Cited by 141
New prospects on the NKG2D/NKG2DL system for oncology
Ullrich, E., Koch, J., Cerwenka, A., & Steinle, A. (2013) · OncoImmunology · doi:10.4161/onci.26097 · Cited by 127
Zafirova, B., Mandarić, S., Antulov, R., Krmpotić, A., Jonsson, H., Yokoyama, W. M., Jonjić, S., & Polić, B. (2009) · Immunity · doi:10.1016/j.immuni.2009.06.017 · Cited by 120
“Various tumor cell lines expressing NKG2D ligands can activate NK or CD8 T cells and induce their cytotoxicity in an NKG2D-dependent manner in vitro as well as in vivo (Bauer et al., 1999; Cerwenka et al., 2001; Diefenbach et al., 2001; Groh et al., 2001).”
BackgroundTargeting Innate Immunity in Cancer Therapy
Rameshbabu, S., Labadie, B. W., Argulian, A., & Patnaik, A. (2021) · Vaccines · doi:10.3390/vaccines9020138 · Cited by 129
“MICA and MICB are polymorphic proteins that are induced upon cell stress, damage or transformation and act as a “kill me” signal through the NKG2D receptor expressed on cytotoxic lymphocytes [221].”
BackgroundPlatelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells
Maurer, S., Kropp, K. N., Klein, G., Steinle, A., Haen, S. P., Walz, J. S., Hinterleitner, C., Märklin, M., Kopp, H., & Salih, H. R. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1364827 · Cited by 127
“Notably, NKG2DL surface expression levels on a given tumor cell directly correlate with the extent of NK cell antitumor reactivity.(5,6) We and others described that surface-”
BackgroundGirart, M. V., Fuertes, M. B., Domaica, C. I., Rossi, L. E., & Zwirner, N. W. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.3472 · Cited by 131
Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy
Knudson, K. M., Hicks, K. C., Alter, S., Schlom, J., & Gameiro, S. R. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0551-y · Cited by 120
Novozhilov, A. S., Berezovskaya, F., Koonin, E. V., & Karev, G. P. (2006) · Biology Direct · doi:10.1186/1745-6150-1-6 · Cited by 117
“Main properties of the system If 1/K ≠ 0 in (4) and there are no infected cells (Y0 = 0), then the tumor grows logistically, X(t) → K when t → ∞; the applicability of this model to some tumors has been demonstrated experimentally [46].”
BackgroundMärten, A., von Lilienfeld‐Toal, M., Büchler, M. W., & Schmidt, J. (2006) · International Journal of Cancer · doi:10.1002/ijc.22186 · Cited by 125
“This tumor escape may be due to several mechanisms: Firstly, shedding of MIC molecules reduces cell surface expression of NKG2DL on tumor cells lead to diminished immunostimulatory signals for cytotoxic lymphocytes.(14,21) In addition, NKG2D-mediated immunity is proposed to be impaired by sMIC via down modulation of N…”
BackgroundLi, C., Ge, B., Nicotra, M. L., Stern, J. N. H., Kopcow, H. D., Chen, X., & Strominger, J. L. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712310105 · Cited by 129
Convergence of Innate and Adaptive Immunity during Human Aging
Pereira, B. I., & Akbar, A. N. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00445 · Cited by 106
“While the general consensus is that NKG2D engagement serves as a costimulatory receptor in CD8+ T cells, amplifying TCR signals in virus-specific responses (58) as well as antitumor immunity (59, 60), other studies have provided compelling evidence that CD8+ T cells may respond to NKG2D ligation alone, without TCR eng…”
BackgroundCrystal Structures of RAE-1β and Its Complex with the Activating Immunoreceptor NKG2D
Li, P., McDermott, G., & Strong, R. K. (2002) · Immunity · doi:10.1016/s1074-7613(02)00258-3 · Cited by 116
“These helices defineRAE-1 molecules can be recognized by NK cells and the groove in which ligand, peptide or otherwise, bindsrejected (Diefenbach et al., 2001).”
Immunosurveillance and immunotherapy of tumors by innate immune cells
Iannello, A., Thompson, T. W., Ardolino, M., Marcus, A., & Raulet, D. H. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.11.001 · Cited by 105
“RAE-1/H60 Melanoma Transferred B16 [6] NKG2D Transd.”
BackgroundSelf-citationFuertes, M. B., Girart, M. V., Molinero, L. L., Domaica, C. I., Rossi, L. E., Barrio, M. M., Mordoh, J., Rabinovich, G. A., & Zwirner, N. W. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4606 · Cited by 105
Intestinal inflammation and colorectal cancer: a double-edged sword?
Rizzo, A., Pallone, F., Monteleone, G., & Fantini, M. C. (2011) · PubMed · doi:10.3748/wjg.v17.i26.3092 · Cited by 107
Gill, S., Olson, J. A., & Negrin, R. S. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.01.019 · Cited by 108
“Tumor cells exhibit differential sensitivity to NK cytotoxicity because of variegated expression of inhibitory and activating receptors on NK cells [23,71], thus NK-mediated clearance of leukemia cells can be augmented by the blockade of inhibitory receptors [110, 111].”
BackgroundBedel, R., Thiery-Vuillemin, A., Grandclément, C., Balland, J., Rémy-Martin, J.-P., Kantelip, B. M., Pallandre, J., Pivot, X. B., Ferrand, C., Tiberghien, P., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-09-4540 · Cited by 113
“NKG2D is an activating receptor shared by NK cells and Tcell lymphocytes, now identified as a pivotal mechanism to prevent the emergence of cancer cells arising following DNA damage induction or spontaneous transformation (7, 9, 16).”
ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15
Sutherland, C. L., Rabinovich, B., Chalupny, N. J., Brawand, P., Miller, R., & Cosman, D. (2006) · Blood · doi:10.1182/blood-2005-11-011320 · Cited by 106
Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy
Zhang, C., & Liu, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01295 · Cited by 113
Novel immune check point inhibiting antibodies in cancer therapy—Opportunities and challenges
Diesendruck, Y., & Benhar, I. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.02.001 · Cited by 114
Cao, W., & Bover, L. C. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00867.x · Cited by 113
Engelhart, M., Lebiedz, D., & Säger, S. (2010) · Mathematical Biosciences · doi:10.1016/j.mbs.2010.11.007 · Cited by 115
“[17].”
CD8 T Cell Help for Innate Antitumor Immunity
Shanker, A., Verdeil, G., Buferne, M., Inderberg-Suso, E.-M., Puthier, D., Joly, F., Nguyen, C., Leserman, L., Auphan-Anezin, N., & Schmitt-Verhulst, A.-M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.10.6651 · Cited by 104
“ory for the parental, nontransfected tumor (16).”
Costimulation of Multiple NK Cell Activation Receptors by NKG2D
Ho, E. L., Carayannopoulos, L. N., Poursine-Laurent, J., Kinder, J., Plougastel, B., Smith, H. R. C., & Yokoyama, W. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.7.3667 · Cited by 105
“NKG2D binds MICA, MICB, and several ULBP molecules, whereas mouse NKG2D binds H60, and several RAE1 family members (45, 46, 52, 70).”
BackgroundNK Cells and Cancer Immunoediting
Guillerey, C., & Smyth, M. J. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_446 · Cited by 111
The changing role of natural killer cells in cancer metastasis
Chan, I. S., & Ewald, A. J. (2022) · Journal of Clinical Investigation · doi:10.1172/jci143762 · Cited by 114
Telomere Length in Human Natural Killer Cell Subsets
OUYANG, Q., BAERLOCHER, G., VULTO, I., & LANSDORP, P. M. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1392.001 · Cited by 100
Selective Induction of Expression of a Ligand for the NKG2D Receptor by Proteasome Inhibitors
Valés-Gómez, M., Chisholm, S. E., Cassady-Cain, R. L., Roda-Navarro, P., & Reyburn, H. T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2973 · Cited by 96
“These observations have profound implications for our understanding of cellular immunity to cancer, because forced expression of NKG2D-L by tumor cells not only leads to enhanced immune-mediated elimination of these tumor cells (38–40) but can also induce adaptive immunity to parental tumor cells that do not express t…”
BackgroundAkazawa, T., Masuda, H., Saeki, Y., Matsumoto, M., Takeda, K., Tsujimura, K., Kuzushima, K., Takahashi, T., Azuma, I., Akira, S., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1518 · Cited by 105
“The most intriguing idea is to use these adjuvant functions to establish an optimal immunotherapy strategy for the host: combined activation of CTLs and NK cells ought to more potently elicit antitumor potential because both MHC-negative and -positive tumor cells can be eliminated as their targets (50, 51).”
BackgroundNK cell heparanase controls tumor invasion and immune surveillance
Putz, E. M., Mayfosh, A. J., Kos, K., Barkauskas, D. S., Nakamura, K., Town, L., Goodall, K. J., Yee, D. Y., Poon, I. K. H., Baschuk, N., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92958 · Cited by 105
RetractedDynamic response of cancer under the influence of immunological activity and therapy
de Vladar, H. P., & González, J. A. (2006) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2005.11.016 · Cited by 105
IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors
Bui, J. D., Carayannopoulos, L. N., Lanier, L. L., Yokoyama, W. M., & Schreiber, R. D. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.2.905 · Cited by 101
“A second reason for the dual modulation relates to the observation that overexpression of NKG2D ligands on targets can lead to NK cell killing even in the presence of high levels of MHC class I (19, 20).”
BackgroundMechanisms of Immune Evasion by Gliomas
Rolle, C. E., Sengupta, S., & Lesniak, M. S. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-3146-6_5 · Cited by 107
Combination Strategies to Enhance Antitumor ADCC
Kohrt, H. E. K., Houot, R., Marabelle, A., Cho, H. J., Osman, K., Goldstein, M. J., Levy, R., & Brody, J. (2012) · Immunotherapy · doi:10.2217/imt.12.38 · Cited by 111
Innate immunity in transplant tolerance and rejection
Murphy, S. P., Porrett, P. M., & Turka, L. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01009.x · Cited by 115
“NK-cell recognition of the induced self-molecule retinoic acid early inducible-1 (Rae-1) by the cognate receptor NKG2D results in the killing of tumor cells (44).”
BackgroundCommon themes in the assembly and architecture of activating immune receptors
Call, M. E., & Wucherpfennig, K. W. (2007) · Nature reviews. Immunology · doi:10.1038/nri2186 · Cited by 112
The NKG2D receptor: immunobiology and clinical implications
Burgess, S. J., Maasho, K., Masilamani, M., Narayanan, S., Borrego, F., & Coligan, J. E. (2007) · Immunologic Research · doi:10.1007/s12026-007-0060-9 · Cited by 114
“In mice, the NKG2D ligands include members of the retinoic acid early (RAE) family of proteins, as well as the minor histocompatibility antigen H60 [25] and the murine ULBP like transcript 1 (MULT1).”
BackgroundCross-talk between dendritic cells and natural killer cells in viral infection
Andrews, D. M., Andoniou, C. E., Scalzo, A. A., van Dommelen, S. L. H., Wallace, M. E., Smyth, M. J., & Degli‐Esposti, M. A. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.07.040 · Cited by 102
Schwinn, N., Vokhminova, D., Sucker, A., Textor, S., Striegel, S., Moll, I., Nausch, N., Tuettenberg, J., Steinle, A., Cerwenka, A., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.24098 · Cited by 118
“It was shown that tumor cells modified to express ligands of the NKG2D receptor are rejected when grafted into mice whereas the parental nonmodified tumor cells form tumors.(12,13) Very recently, Guerra et al.”
BackgroundPhilpott, M., & Ferguson, L. (2004) · Mutation research · doi:10.1016/j.mrfmmm.2004.03.005 · Cited by 106
DeMarco, R., Fink, M. P., & Lotze, M. T. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.07.023 · Cited by 110
The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy
Yu, Y. (2023) · Cancers · doi:10.3390/cancers15082323 · Cited by 107
Whang, M. I., Guerra, N., & Raulet, D. H. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802439 · Cited by 98
“Daudi, RMA, Pam, and PDV cells were transduced with replication-deficient retroviruses encoding H60c (pMSCV-H60c) or Rae1 (pMSCV-Rae1 ), as described previously (23).”
BackgroundMethodSelf-citationCurrent concepts of tumor-infiltrating lymphocytes in human malignancies
Chiou, S., Sheu, B., Chang, W., Huang, S., & Ho, H. (2005) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2005.06.002 · Cited by 108
“According to this hypothesis, strong immune responses as well as AICD possibly happens early stages of tumor progression when the immunogenicity of cancer cells may be enhanced by IFN- production from innate immune cells (Diefenbach et al., 2001).”
BackgroundMultiplicity and plasticity of natural killer cell signaling pathways
Chiesa, S., Mingueneau, M., Fuseri, N., Malissen, B., Raulet, D. H., Malissen, M., Vivier, E., & Tomasello, E. (2006) · Blood · doi:10.1182/blood-2005-08-3504 · Cited by 89
“3x 10(5) B16, B16-H60 or B16-Rae1β melanoma cells were injected intravenously in the retro-orbital sinus of anesthetized mice.(35) Lung metastases were evaluated 15 days after injection.”
MethodSelf-citationLamb, L. S., Bowersock, J., Dasgupta, A., Gillespie, G. Y., Su, Y. Y., Johnson, A., & Spencer, H. T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0051805 · Cited by 104
“Such tumors are also often rejected during transplantation [45], while tumorigenesis is favored in mice that lack the expression of NKG2D receptors [46].”
BackgroundNatural killer cells in rejection and tolerance of solid organ allografts
Benichou, G., Yamada, Y., Aoyama, A., & Madsen, J. (2011) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e32834254cf · Cited by 92
Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy
Luna, J. I., Grossenbacher, S. K., Murphy, W. J., & Canter, R. J. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1271874 · Cited by 100
“NK-cell-mediated rejection of tumors in other mouse tumor models [61].”
BackgroundInnate immune recognition by stimulatory immunoreceptors
Diefenbach, A., & Raulet, D. H. (2003) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00007-9 · Cited by 108
Self-citationCytosolic PLA2 is required for CTL-mediated immunopathology of celiac disease via NKG2D and IL-15
Tang, F., Chen, Z., Ciszewski, C., Setty, M., Solus, J., Tretiakova, M., Ebert, E., Han, J., Lin, A., Guandalini, S., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20071887 · Cited by 94
Upshaw, J. L., & Leibson, P. J. (2006) · Seminars in Immunology · doi:10.1016/j.smim.2006.03.001 · Cited by 114
Duan, X., Deng, L., Chen, X., Lu, Y., Zhang, Q., Zhang, K., Hu, Y., Zeng, J., & Sun, W. (2010) · Medical Oncology · doi:10.1007/s12032-010-9480-9 · Cited by 97
“Two mechanisms have been proposed, by which, shedding of MICA leads to decreased NKG2DL expression levels on the tumor cell surface, which directly affects tumor cell lysis [18].”
BackgroundRegulation of NKG2D-Dependent NK Cell Functions: The Yin and the Yang of Receptor Endocytosis
Molfetta, R., Quatrini, L., Santoni, A., & Paolini, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081677 · Cited by 103
“Ectopic expression of NKG2D ligands (NKG2DLs) causes tumor rejection in syngeneic mouse models despite MHC class I expression [6,7], while NKG2D deficiency impairs surveillance towards spontaneous malignancies [8,9].”
BackgroundPosttranslational regulation of the NKG2D ligand Mult1 in response to cell stress
Nice, T. J., Coscoy, L., & Raulet, D. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081335 · Cited by 98
Self-citationCancer vaccines: progress reveals new complexities
Yu, Z., & Restifo, N. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16216 · Cited by 107
“NKG2D receptors expressed by NK cells and activated CD8+ T cells and macrophages can be stimulated by their ligands, which are often overexpressed on cancer cell lines (18).”
BackgroundHallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications
Xiao, T., Lee, J., Gauntner, T. D., Velegraki, M., Lathia, J. D., & Li, Z. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00680-z · Cited by 99
“As natural killer cells have been well reported to elicit direct antitumour capacity in various syn-genetic mouse tumour models 91–94 , it is thus reasonable to postulate that oestrogen can impair natural killer-mediated antitumour function.”
OPTIMAL CONTROL OF MIXED IMMUNOTHERAPY AND CHEMOTHERAPY OF TUMORS
de Pillis, L. G., Fister, K. R., GU, W., Head, T., MAPLES, K., Neal, T., Murugan, A., & Kozai, K. (2008) · Journal of Biological Systems · doi:10.1142/s0218339008002435 · Cited by 103
Zocchi, M. R., Catellani, S., Canevali, P., Tavella, S., Garuti, A., Villaggio, B., Zunino, A., Gobbi, M., Orcioni, G. F., Kunkl, A., et al. (2011) · Blood · doi:10.1182/blood-2011-07-370841 · Cited by 96
Cytokine-driven regulation of NK cell functions in tumor immunity: Role of the MICA-NKG2D system
Zwirner, N. W., Fuertes, M. B., Girart, M. V., Domaica, C. I., & Rossi, L. E. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.01.013 · Cited by 100
“[21] Diefenbach A, Jensen ER, Jamieson AM, Raulet DH.”
BackgroundMcGilvray, R. W., Eagle, R. A., Rolland, P., Jafferji, I., Trowsdale, J., & Durrant, L. G. (2010) · International Journal of Cancer · doi:10.1002/ijc.25156 · Cited by 104
Hervieu, A., Rébé, C., Végran, F., Chalmin, F., Bruchard, M., Vabres, P., Apétoh, L., Ghiringhelli, F., & Mignot, G. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.273 · Cited by 97
“The expression of NKG2D ligands in cells that do not express them endogenously renders the cells more prone to NK cell–mediated lysis in vitro, and reduces the tumorigenicity of tumor cell lines in vivo (Cerwenka et al., 2000, 2001; Diefenbach et al., 2000, 2001).”
BackgroundDAP12: an adapter protein with dual functionality
Takaki, R., Watson, S. R., & Lanier, L. L. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00466.x · Cited by 93
Tietze, J. K., Wilkins, D. E. C., Sckisel, G. D., Bouchlaka, M. N., Alderson, K. L., Weiss, J. M., Ames, E., Bruhn, K. W., Craft, N., Wiltrout, R. H., et al. (2012) · Blood · doi:10.1182/blood-2011-07-369736 · Cited by 94
NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy
Malmberg, K., Bryceson, Y. T., Carlsten, M., Andersson, S., Björklund, A. T., Björkström, N. K., Baumann, B. C., Fauriat, C., Alici, E., Dilber, M. S., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0492-7 · Cited by 98
“, for NKG2D-mediated triggering of some MHC class I expressing tumor cell lines [23, 31].”
A mathematical model of immune response to tumor invasion
de Pillis, L. G., & Radunskaya, A. (2003) · Elsevier eBooks · doi:10.1016/b978-008044046-0.50404-8 · Cited by 94
“[1], in which mouse tumor cell lines are modified to express higher levels of immune stimulating NKG2D ligands.”
BackgroundMethodInfluentialMathematical model of tumor–immune surveillance
Mahasa, K. J., Ouifki, R., Eladdadi, A., & de Pillis, L. G. (2016) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2016.06.012 · Cited by 102
Interleukin-17D Mediates Tumor Rejection through Recruitment of Natural Killer Cells
O’Sullivan, T., Saddawi-Konefka, R., Gross, E., Tran, M., Mayfield, S. P., Ikeda, H., & Bui, J. D. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.073 · Cited by 88
“Because it is known that NK-dependent tumor rejection can lead to priming of adaptive immune responses (Diefenbach et al., 2001; Kelly et al., 2002), we then tested whether mice that had rejected IL-17D-overexpressing tumors could reject a rechallenge with untransduced progressor tumors.”
BackgroundBeyond Stressed Self: Evidence for NKG2D Ligand Expression on Healthy Cells
Eagle, R. A., Jafferji, I., & Barrow, A. D. (2009) · Current Immunology Reviews · doi:10.2174/157339509787314369 · Cited by 101
“There is also evidence that NKG2D participates in anti-cancer immune responses in vivo [24-26].”
BackgroundGünther, S., Ostheimer, C., Stangl, S., Specht, H. M., Mózes, P., Jesinghaus, M., Vordermark, D., Combs, S. E., Peltz, F., Jung, M. P., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00556 · Cited by 91
“Experimental mouse models indicate that the development of tumor-specific CD8+ cytotoxic T cell responses is highly dependent on the NK cell-mediated elimination of tumor cells (43, 44) through the secretion of IFN-γ.”
BackgroundITAM-based signaling beyond the adaptive immune response
Fodor, S., Jakus, Z., & Mócsai, A. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.11.001 · Cited by 102
Choi, E. Y., Christianson, G. J., Yoshimura, Y., Sproule, T. J., Jung, N., Joyce, S., & Roopenian, D. C. (2002) · Immunity · doi:10.1016/s1074-7613(02)00428-4 · Cited by 91
MICA/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer
Cho, H., Chung, J., Kim, S., Braunschweig, T. A., Kang, T. H., Kim, J., Chung, E. J., Hewitt, S. M., & Kim, J.-H. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-957 · Cited by 95
“In addition, these in vivo cancer models also strongly suggest that the activating immune receptor NKG2D stimulates anti-cancer immune responses [22-24].”
BackgroundThe BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity
Salih, J., Hilpert, J., Placke, T., Grünebach, F., Steinle, A., Salih, H. R., & Krusch, M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25233 · Cited by 98
NKG2D and cytotoxic effector function in tumor immune surveillance
Hayakawa, Y., & Smyth, M. J. (2006) · Seminars in Immunology · doi:10.1016/j.smim.2006.03.005 · Cited by 106
Gentilini, A., Pastore, M., Marra, F., & Raggi, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102885 · Cited by 84
“The NK pathway is mediated by NKG2D (natural-killer group 2D) [48], a lectin-like activating receptor.”
BackgroundThe Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer
Nair, S. S., Weil, R., Dovey, Z. S., Davis, A., & Tewari, A. K. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.10.005 · Cited by 98
How to improve the immunogenicity of chemotherapy and radiotherapy
Ma, Y., Conforti, R., Aymeric, L., Locher, C., Kepp, O., Kroemer, G., & Zitvogel, L. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9283-2 · Cited by 92
“the expression of NKG2D ligands on tumor cells [79].”
BackgroundThe Natural Killer Cell – Friend or Foe in Autoimmune Disease?
Flodström‐Tullberg, M., Shi, F., Sarvetnick, N., & Ljunggren, H. (2002) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2002.01084.x · Cited by 94
A Review of Mathematical Models of Cancer–Immune Interactions in the Context of Tumor Dormancy
Wilkie, K. P. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-1445-2_10 · Cited by 88
“[63], the assumption”
Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer
Hu, Z. I., Ho, A. Y., & McArthur, H. L. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.05.029 · Cited by 90
Metadata
- Authors
- Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H.
- Affiliations
- University of California, Berkeley (US)
- Corresponding author
- Raulet, David H.
- Venue
- Nature
- Published
- 2001-09-13
- Volume
- 413
- Issue
- 6852
- Pages
- 165-171
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3900321
- OpenAlex
- W1595098530
- Cited by
- 1,083
- References
- 30
- Citations by year
- 2026: 17 · 2025: 28 · 2024: 26 · 2023: 38 · 2022: 28 · 2021: 43 · 2020: 48 · 2019: 37 · 2018: 38 · 2017: 32 · 2016: 34 · 2015: 53 · 2014: 42 · 2013: 48 · 2012: 42
- FWCI
- 15.26
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- National Institute of Allergy and Infectious Diseases (R01AI039642)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- NKG2D, Rae1, NKG2D ligands, natural killer cells, tumour immunity, tumor rejection, CD8+ T cells, cancer vaccines, MHC class I
- MeSH terms
- Animals, Cytotoxicity, Immunologic, Immunity, Killer Cells, Natural, Ligands, Membrane Proteins, Mice, Inbred C57BL, Neoplasms, Receptors, Immunologic, Recombinant Proteins, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, Minor Histocompatibility Antigens, CD8-Positive T-Lymphocytes, Mice, Receptors, Natural Killer Cell, NK Cell Lectin-Like Receptor Subfamily K
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.